Allergan acquires Chase for a possible $1bn
Executive Summary
Allergan PLC acquired private neurodegenerative therapeutics biotech Chase Pharmaceuticals Corp. (focused improving the symptomatic treatment of Alzheimer’s disease) for up to $1bn.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Transdermal
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Earnout
- Payment Includes Cash for Equity
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice